Corcept Therapeutics Inc
1CORT
Company Profile
Business description
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Contact
101 Redwood Shores Parkway
Redwood CityCA94065
USAT: +1 650 327-3270
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
500
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,096.20 | 77.60 | 0.86% |
| CAC 40 | 8,103.85 | 17.22 | -0.21% |
| DAX 40 | 24,314.48 | 30.51 | 0.13% |
| Dow JONES (US) | 48,362.68 | 227.79 | 0.47% |
| FTSE 100 | 9,869.47 | 3.50 | 0.04% |
| HKSE | 25,774.14 | 27.63 | -0.11% |
| NASDAQ | 23,428.83 | 121.21 | 0.52% |
| Nikkei 225 | 50,412.87 | 10.48 | 0.02% |
| NZX 50 Index | 13,517.73 | 9.43 | 0.07% |
| S&P 500 | 6,878.49 | 43.99 | 0.64% |
| S&P/ASX 200 | 8,795.70 | 78.80 | 0.90% |
| SSE Composite Index | 3,919.98 | 2.61 | 0.07% |